Xeris Biopharma Holdings Executive Compensation
Xeris Biopharma Holdings appointed Menassie Taddese to its Board of Directors and Audit Committee, effective November 2, 2026. In connection with his appointment, Mr. Taddese received an initial equity award of options and RSUs with a grant date fair value of approximately $450,000 and will be eligible for annual equity grants of $300,000. Mr. Taddese brings nearly 30 years of experience from leadership roles at Viatris and Pfizer.
- Counterparty
- Menassie Taddese